Syndax Pharmaceuticals, Inc.
$23.78
▲
5.32%
2026-04-21 09:31:00
syndax.com
NMS: SNDX
Explore Syndax Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.1 B
Current Price
$23.78
52W High / Low
$25.59 / $8.58
Stock P/E
—
Book Value
$0.74
Dividend Yield
—
ROCE
-66.67%
ROE
-1.62%
Face Value
—
EPS
$-3.29
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
298
Beta
0.41
Debt / Equity
534.48
Current Ratio
4.4
Quick Ratio
4.12
Forward P/E
-40.92
Price / Sales
12.51
Enterprise Value
$2.09 B
EV / EBITDA
-7.63
EV / Revenue
12.11
Rating
Strong Buy
Target Price
$39
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | MeiraGTx Holdings plc | $10.53 | — | $857.63 M | — | -86.95% | -3.68% | $11.85 / $4.55 | $-0.07 |
| 2. | KalVista Pharmaceuticals, Inc. | $20.87 | — | $1.07 B | — | -89% | -121.5% | $21.3 / $9.83 | $-0.05 |
| 3. | Krystal Biotech, Inc. | $276.4 | 40.42 | $8.11 B | — | 13.1% | 18.91% | $298.3 / $122.8 | $41.78 |
| 4. | ImageneBio, Inc. | $6 | — | $65.99 M | — | -34.18% | -68.91% | $18 / $3.94 | $11.91 |
| 5. | Zentalis Pharmaceuticals, Inc. | $4.03 | — | $301.33 M | — | -57.45% | -49.54% | $6.95 / $1.13 | $3.13 |
| 6. | Foghorn Therapeutics Inc. | $5.51 | — | $310.52 M | — | -59.34% | 96.45% | $6.95 / $3.27 | $-1.92 |
| 7. | Daré Bioscience, Inc. | $2.87 | — | $41.79 M | — | -154.2% | 845.53% | $9.19 / $1.27 | $0.2 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 68.73 M | 45.87 M | 37.96 M | 20.04 M | 7.68 M |
| Operating Profit | -62.55 M | -57.43 M | -69.35 M | -83.76 M | -96.36 M |
| Net Profit | -68.01 M | -60.72 M | -71.85 M | -84.85 M | -94.17 M |
| EPS in Rs | -0.77 | -0.69 | -0.81 | -0.96 | -1.07 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 172.35 M | 23.68 M | 0 M | 0 M |
| Operating Profit | -273.08 M | -339.67 M | -229.95 M | -151.76 M |
| Net Profit | -285.42 M | -318.76 M | -209.36 M | -149.34 M |
| EPS in Rs | -3.24 | -3.61 | -2.37 | -1.69 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 529.71 M | 724.82 M | 612.88 M | 497.24 M |
| Total Liabilities | 465.08 M | 436.69 M | 58.68 M | 29.79 M |
| Equity | 64.63 M | 288.12 M | 554.2 M | 467.45 M |
| Current Assets | 528.08 M | 603.06 M | 580.88 M | 489.79 M |
| Current Liabilities | 120.12 M | 103.55 M | 58.1 M | 29.07 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -322.98 M | -274.9 M | -160.6 M | -133.68 M |
| Investing CF | 290.04 M | -219.78 M | 117.61 M | -186.19 M |
| Financing CF | 13.68 M | 353.37 M | 264.13 M | 172.25 M |
| Free CF | -323.17 M | -274.9 M | -160.6 M | -133.68 M |
| Capex | -0.19 M | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -52.25% | -40.19% | — | — |
| Profit Margin % | -1346.11% | — | — | — |
| Operating Margin % | -1434.43% | — | — | — |
| Gross Margin % | 96.51% | — | — | — |
| EBITDA Margin % | -1325.25% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.